Abbvie presents venetoclax Stage 1 results in sufferers with multiple myeloma in ASCO 2015 AbbVie.

Generated record operating cash flow of $23.4 million. Completed the acquisition of Hi-Tech Pharmacal Co., Inc. on April 17. The acquisition adds level, breadth of items and dosage forms, and further diversification of the Firm's item portfolio. Raj Rai, Chief Executive Officer commented, ‘We are thrilled with the great start that we've seen for 2014. We proceeds to execute on multiple development initiatives. In addition to completing the transformative acquisition of Hi-Tech a few weeks ago, we also obtained two more top quality ophthalmic products, getting to five the top quality ophthalmic products acquired over the last few months. The acquisition of Hi-Tech further diversifies our niche branded and generic product base and brings with it capabilities that will help us continue to grow and diversify our pipeline and income base into the future.’ Financial Outcomes for the One fourth Ended March 31, 2014 Consolidated revenue for the first one fourth of 2014 was $90.6 million, a rise of 23 percent over the first quarter 2013 consolidated revenue of $73.9 million.The objective of widespread EHR adoption, as envisioned by the Obama administration in 2008, was allowing a changeover from volume-structured to value-based payments: an electronic infrastructure was needed for measuring quality. At the right time, however, less than 17 percent of physician methods were using EHRs, and their systems lacked necessary data-capture capabilities often. Given the high up-entrance costs and uncertainty relating to future returns, cultural and monetary hurdles to adoption were formidable. Wachter interviewed three former national coordinators for wellness it : the libertarian-inclined David Brailer, who provides such faith in market-driven advancement that he believed in the business he was leading hardly; David Blumenthal, the consummate diplomat, whose $30 billion budget was 71,000 percent higher than Brailer’s and who, in precipitating widespread adoption, was arguably the most successful leader; and Farzad Mostashari, perhaps the most controversial, whose hard-line insistence on the importance of Meaningful Use 2 has been widely criticized.